Director/PDMR Shareholding

RNS Number : 7661R
Reckitt Benckiser Group PLC
04 March 2019
 

 

                                                                                                             4 March 2019

 

RECKITT BENCKISER GROUP PLC

 DIRECTOR/PDMR SHAREHOLDINGS

 

Reckitt Benckiser Group plc (the "Company" or "RB") announces the following change in the interests of a Director in ordinary shares of 10 pence each in the share capital of the Company ("Shares").

 

   The Company was notified on 1 March 2019 that Dr Mehmood Khan, Independent Non-Executive Director, purchased a total of 80 Shares on 28 February 2019 at £58.202 per share. 

 

     This was in relation to his 2018 remuneration. The remuneration of RB's Non-Executive Directors includes fees which are to be used in the purchase of Shares.   Approximately 18% of the Non-Executive Directors' base fee (net) is invested in Shares which they are expected to retain for the duration of their tenure.    The percentage of Dr Khan's fees applied in this way were pro-rated based on his appointment to the Board on 1 July 2018.   

 

   Following this transaction, Dr Khan has a beneficial holding of 80 Shares in the Company, representing 0.00001%  of the total voting rights of the Company.  

 

The following notification is made in accordance with the requirements of the EU Market Abuse Regulation.

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mehmood Khan

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/
Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Reckitt Benckiser Group plc

b)

LEI

5493003JFSMOJG48V108

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 10p each in Reckitt Benckiser Group plc

GB00B24CGK77

b)

Nature of the transaction

Purchase of shares as part of requirement for percentage of base fee to invested in shares in relation to 2018 fees (following applicable withholdings in respect of any tax liability) (pro-rated based on 18% for NED)

c)

Price(s) and volume(s)

Price(s)

Volume(s)

GBP 58.202

80

 

d)

Aggregated information

-       Aggregated volume

-       Price

n/a

 

 

e)

Date of the transaction

2019-02-28

f)

Place of the transaction

London Stock Exchange, Main Market - XLON

 

 

 

For further Information:
Christine Logan

Deputy Company Secretary
Tel +44 (0) 1753 217 800

 

Richard Joyce

SVP, Investor Relations

Tel. +44 (0)1753 217 800

 

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

 

 

About RB:

RB* is the global leading consumer health, hygiene and home company. Driven by a purpose of providing innovative solutions for healthier lives and happier homes, RB has operations in over 60 countries.  From the foundations of wellness and infant nutrition, to the fundamentals of a hygienic home, its global brands help people live healthier, happier lives.

RB has world leading Powerbrands which include household names such as Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Cillit Bang, Mortein, Finish, Vanish, Calgon, Woolite and Air Wick.

RB's unique culture is at the heart of its success.  Its drive to achieve, passion to outperform and commitment to quality and scientific excellence is manifested in the work of over 40,000 employees worldwide. 

For more information visit www.rb.com 

 

*RB is the trading name of the Reckitt Benckiser group of companies

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBBGDXCXGBGCS
UK 100

Latest directors dealings